Optimized administration of human embryonic stem cell-derived immunity-and-matrix regulatory cells for mouse lung injury and fibrosis

Dingyun Song,Zhongwen Li,Faguo Sun,Kaiwei Wu,Kan Zhang,Wenjing Liu,Kaidi Liu,Bin An,Zai Wang,Tiemei Zhao,Huaiyong Chen,Li Xiao,Liu Wang,Lixin Xie,Wei Li,Liang Peng,Jie Hao,Jun Wu,Huaping Dai
DOI: https://doi.org/10.1186/s13287-024-03945-4
2024-10-10
Stem Cell Research & Therapy
Abstract:Lung injury and pulmonary fibrosis (PF), frequently arising as sequelae of severe and acute lung disease, currently face a dearth of effective therapeutic potions. Mesenchymal stem cells (MSCs) with immunomodulatory and tissue repair functions have immense potential to treat lung injury and PF. However, the optimal route of administration, timing, and frequency of dosing remain elusive. Human embryonic stem cell-derived immunity-and-matrix-regulatory cells (IMRCs) have shown therapeutic potential for lung injury and PF.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?